Insight

On April 23, 2024, Optimat’s life sciences consultant Jolanta Beinaroviƒça had the privilege of attending the second Oligonucleotide Manufacturing Symposium organised by the CPI’s Medicines Manufacturing Innovation Centre. The event brought together a diverse group of stakeholders from the pharmaceutical sector, chemical engineering, and regulations to discuss and explore cutting-edge process technologies in oligonucleotide production. The symposium boasted an impressive lineup of speakers, including industry leaders such as Novo Nordisk, YpsoFakto, and Bryden Wood. They provided invaluable insights into the challenges and advancements in the manufacturing of oligonucleotides‚Äîa promising novel class of therapeutics with the potential to revolutionise treatments for a multitude of diseases. The day was filled with engaging presentations and dynamic panel discussions focusing on critical issues like solvent use, regulatory compliance, and process engineering.

‘The themes of modularisation and systematisation are deeply embedded in the field of oligonucleotides, from molecule design to lean manufacturing and process engineering. It is fascinating how the industry matures, navigating supply chain pressures and net-zero challenges. The synergistic opportunity between oligonucleotide manufacturing and engineering biology sectors is massive, and we as innovation intermediates need to ensure that the indigenous UK industrial biotech sector capitalises on this growing high-value market.’ says Jolanta.